<DOC>
	<DOCNO>NCT01524575</DOCNO>
	<brief_summary>The goal clinical trial improve personalize pancreatic cancer care deliver effective therapy avoid unnecessary exposure potential side effect . Excision repair cross-complementation group 1 ( ERCC1 ) protein mRNA expression predict response oxaliplatin - patient whose cancer make small amount ERCC1 much likely respond cisplatin whose tumor produce large amount . The hypothesis combination gemcitabine oxaliplatin uniquely effective regimen patient metastatic pancreatic cancer whose tumor low expression ERCC1 .</brief_summary>
	<brief_title>Gemcitabine Oxaliplatin Management Metastatic Pancreatic Cancers With Low Expression ERCC1</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically cytologically confirm metastatic pancreatic adenocarcinoma Patients must prior chemotherapy biologic therapy metastatic pancreatic cancer Prior adjuvant chemotherapy completely resect disease chemoradiotherapy locally advanced disease allow must administer &gt; 6 month prior registration ECOG Performance Status 0 , 1 , 2 Adequate hematologic , hepatic renal function Pregnant nursing woman No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 5 year Patients must know brain metastasis Any condition opinion Investigator may render patient excessive risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>ERCC1</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>gemcitabine</keyword>
</DOC>